Beddow Capital Management Inc. Boosts Stake in Organon & Co. (NYSE:OGN)

Beddow Capital Management Inc. raised its holdings in Organon & Co. (NYSE:OGN - Free Report) by 41.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 432,300 shares of the company's stock after purchasing an additional 125,625 shares during the quarter. Organon & Co. accounts for about 2.7% of Beddow Capital Management Inc.'s holdings, making the stock its 15th biggest position. Beddow Capital Management Inc. owned approximately 0.17% of Organon & Co. worth $6,450,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Barclays PLC grew its holdings in Organon & Co. by 238.0% in the third quarter. Barclays PLC now owns 119,483 shares of the company's stock valued at $2,285,000 after purchasing an additional 84,136 shares during the last quarter. Weiss Asset Management LP purchased a new position in Organon & Co. during the third quarter worth $32,966,000. Cerity Partners LLC raised its holdings in shares of Organon & Co. by 94.0% in the third quarter. Cerity Partners LLC now owns 667,340 shares of the company's stock worth $12,766,000 after acquiring an additional 323,308 shares during the last quarter. Robeco Institutional Asset Management B.V. purchased a new stake in shares of Organon & Co. in the fourth quarter valued at $2,263,000. Finally, Victory Capital Management Inc. boosted its stake in shares of Organon & Co. by 127.3% during the third quarter. Victory Capital Management Inc. now owns 183,298 shares of the company's stock valued at $3,506,000 after acquiring an additional 102,663 shares during the last quarter. Institutional investors and hedge funds own 77.43% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

A number of research firms have issued reports on OGN. Barclays reduced their target price on shares of Organon & Co. from $26.00 to $24.00 and set an "overweight" rating on the stock in a report on Friday, February 14th. Morgan Stanley reduced their price objective on shares of Organon & Co. from $17.00 to $16.00 and set an "equal weight" rating on the stock in a research note on Friday, February 14th. Finally, TD Cowen raised shares of Organon & Co. to a "hold" rating in a research note on Wednesday, January 15th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, two have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $20.80.

Organon & Co. Trading Down 3.8 %

NYSE:OGN traded down $0.59 during trading hours on Tuesday, reaching $14.74. 3,416,269 shares of the company were exchanged, compared to its average volume of 2,416,978. The firm has a market cap of $3.80 billion, a price-to-earnings ratio of 4.43, a PEG ratio of 0.90 and a beta of 0.76. The stock has a 50 day simple moving average of $15.41 and a 200 day simple moving average of $16.33. Organon & Co. has a 52-week low of $13.87 and a 52-week high of $23.10. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21.

Organon & Co. (NYSE:OGN - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing analysts' consensus estimates of $0.92 by ($0.09). Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. The business had revenue of $1.59 billion for the quarter, compared to analysts' expectations of $1.57 billion. As a group, analysts predict that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 13th. Shareholders of record on Monday, February 24th were issued a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a yield of 7.60%. The ex-dividend date was Monday, February 24th. Organon & Co.'s dividend payout ratio is presently 33.63%.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.